Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
We report the outcomes of six older adults at high risk of anthracycline-induced cardiotoxicity who received dexrazoxane during induction/re-induction therapy. Five had preserved left-ventricular function while two proceeded onto stem-cell transplantation. Additional investigation of dexrazoxane in adult leukemia therapy is warranted, particularly in older patients at highest risk for cardiovascular mortality.
Source: Leukemia Research Reports - Category: Hematology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cardiology | Cardiovascular | Heart | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants